Cell proliferation in human tumour xenografts: measurement using antibody labelling against bromodeoxyuridine and Ki-67.
Cell proliferation was investigated in human tumour xenografts using bromodeoxyuridine (BrdUrd) labelling, evaluated either by flow cytometry or in tissue sections, and also using the proliferation marker Ki-67. BrdUrd labelling was found to increase when cryostat tumour sections were digested with an enzymic solution. This yielded a labelling index up to four times higher than that obtained using the flow cytometer. Ki-67 indices were found to be higher than those reported for human tumour biopsies, as may be expected due to the enhanced growth rate of the xenografts. Significant heterogeneity was observed in the results for cervix, breast and bladder tumours, and the results of the three methods were poorly correlated. However, three of the four tumour types showed that the tumour with the lowest Ki-67 index also had the longest potential doubling time. Since the measurement of Ki-67 index was found technically easier to perform, and also adequately reflects relative tumour cell proliferation, it is preferred over the other techniques.
Parkins
C S
CS
Radiotherapy Research Unit, Institute of Cancer Research, Sutton, Surrey, UK.
Bush
C
C
Price
P
P
Steel
G G
GG
D000818:Animals; D000911:Antibodies, Monoclonal; D001943:Breast Neoplasms / Q000473:pathology; D001973:Bromodeoxyuridine / Q000276:immunology / Q000378:metabolism*; D002453:Cell Cycle; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000473:pathology*; D009687:Nuclear Proteins / Q000276:immunology / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000473:pathology
D000911:Antibodies, Monoclonal; D019394:Ki-67 Antigen; D009687:Nuclear Proteins; D001973:Bromodeoxyuridine